Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; its reference list is not available; 94 of the 196 sources its claims cite were checked for support.

Dietary sugar consumption and health: umbrella review

Open access

Abstract

Objective: To evaluate the quality of evidence, potential biases, and validity of all available studies on dietary sugar consumption and health outcomes. Design: Umbrella review of existing meta-analyses. Data sources: PubMed, Embase, Web of Science, Cochrane Database of Systematic Reviews, and hand searching of reference lists. Inclusion criteria: Systematic reviews and meta-analyses of randomised controlled trials, cohort studies, case-control studies, or cross sectional studies that evaluated the effect of dietary sugar consumption on any health outcomes in humans free from acute or chronic diseases. Results: The search identified 73 meta-analyses and 83 health outcomes from 8601 unique articles, including 74 unique outcomes in meta-analyses of observational studies and nine unique outcomes in meta-analyses of randomised controlled trials. Significant harmful associations between dietary sugar consumption and 18 endocrine/metabolic outcomes, 10 cardiovascular outcomes, seven cancer outcomes, and 10 other outcomes (neuropsychiatric, dental, hepatic, osteal, and allergic) were detected. Moderate quality evidence suggested that the highest versus lowest dietary sugar consumption was associated with increased body weight (sugar sweetened beverages) (class IV evidence) and ectopic fatty accumulation (added sugars) (class IV evidence). Low quality evidence indicated that each serving/week increment of sugar sweetened beverage consumption was associated with a 4% higher risk of gout (class III evidence) and each 250 mL/day increment of sugar sweetened beverage consumption was associated with a 17% and 4% higher risk of coronary heart disease (class II evidence) and all cause mortality (class III evidence), respectively. In addition, low quality evidence suggested that every 25 g/day increment of fructose consumption was associated with a 22% higher risk of pancreatic cancer (class III evidence). Conclusions: High dietary sugar consumption is generally more harmful than beneficial for health, especially in cardiometabolic disease. Reducing the consumption of free sugars or added sugars to below 25 g/day (approximately 6 teaspoons/day) and limiting the consumption of sugar sweetened beverages to less than one serving/week (approximately 200-355 mL/week) are recommended to reduce the adverse effect of sugars on health. Systematic review registration: PROSPERO CRD42022300982.

Overview

CoChat Summary

TL;DR

This umbrella review of 73 meta-analyses found that high dietary sugar consumption was generally more harmful than beneficial across 83 health outcomes, especially cardiometabolic disease. Most evidence was low or very low quality, with no high-quality or class I evidence identified.

Key findings

  • From 8601 unique articles, the review included 73 meta-analyses and 83 health outcomes: 74 outcomes from observational-study meta-analyses and 9 from randomised controlled trial meta-analyses. Significant harmful associations were found for 18 endocrine/metabolic, 10 cardiovascular, 7 cancer, and 10 other outcomes.
  • Moderate-quality evidence linked highest versus lowest sugar sweetened beverage consumption to increased body weight (weighted mean difference 0.85, 95% CI 0.50 to 1.20) and added sugar consumption to ectopic fat accumulation (liver fat standardised mean difference 0.93, 95% CI 0.64 to 1.21; muscle fat 0.63, 95% CI 0.23 to 1.04).
  • Low-quality evidence indicated each serving/week increment of sugar sweetened beverages was associated with 4% higher gout risk (RR 1.04, 95% CI 1.02 to 1.07); each 250 mL/day increment was associated with 17% higher coronary heart disease risk (RR 1.17, 95% CI 1.11 to 1.23) and 4% higher all-cause mortality (HR 1.04, 95% CI 1.02 to 1.06); each 25 g/day increment of fructose was associated with 22% higher pancreatic cancer risk (RR 1.22, 95% CI 1.08 to 1.37).
  • The authors recommend reducing free or added sugars to below 25 g/day (about 6 teaspoons/day) and limiting sugar sweetened beverages to less than one serving/week (about 200-355 mL/week). No high-quality or class I evidence was found; most outcomes were low or very low quality and class III, IV, or non-significant.

Methods

  • Design: umbrella review of existing systematic reviews and meta-analyses, prospectively registered in PROSPERO (CRD42022300982).
  • Data sources: PubMed, Embase, Web of Science, and Cochrane Database of Systematic Reviews from inception through January 2022, plus hand searching of reference lists.
  • Inclusion: systematic reviews and meta-analyses of randomised controlled trials, cohort, case-control, or cross-sectional studies evaluating dietary sugar consumption and any health outcome in humans free from acute or chronic diseases. Two reviewers independently screened, extracted data, and assessed quality using AMSTAR, GRADE, and evidence classification criteria; effects were reanalysed with random or fixed effects models, heterogeneity, and publication bias tests where possible.

Limitations

  • The paper states that original studies used different dietary assessment methods (food records, 24-hour recall, food frequency questionnaires, dietary history), causing unavoidable measurement bias; most studies focused on beverages pre-sweetened before purchase; and the review could not evaluate sugars in some foods such as chocolate and ice cream because sugar consumption data could not be extracted.
  • The paper states that sugar sweetened beverage types and dosages varied, exposure units differed across studies, and dose-response or stratification analyses by beverage type were unavailable for most outcomes; other compounds in sugar sweetened beverages (e.g., 4-methylimidazole, pesticides, artificial sweeteners, sodium benzoate, sulfites) may confound effects. It also states that original studies’ competing interests were not investigated, and only two included meta-analyses were funded by sugar sweetened beverage companies, one of which was selected for data extraction.
  • Evident in the text: the review depends on the quality of included meta-analyses; all observational evidence was graded low or very low, no high-quality or class I evidence was found, about 46% of reanalysed outcomes had significant heterogeneity, and publication bias was detected for some outcomes including type 2 diabetes mellitus (sugar sweetened beverages), overall cancer risk, and hypertension in adults (sugar sweetened beverages).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/bmj-2022-071609

Cites

Statistics

Nothing to recompute.

Figures

Fig 1 Flowchart of systematic search and selection process
Fig 1 Flowchart of systematic search and selection processCC BY · PubMed Central
Fig 2 Significant dose-response relations between dietary sugar consumption and multiple health outcomes. Estimates are relative risks, summary mean difference is weighted mean difference, and effect models are random unless noted otherwise. Δ=final value – baseline value; AMSTAR=a measurement tool to assess systematic reviews; C=cohort studies; CHD=coronary heart disease; CI=confidence interval; CVD=cardiovascular disease; GRADE=Grading of Recommendations Assessment, Development and Evaluation; NA=not available; P=population based case-control and/or cross sectional studies; SSB=sugar sweetened beverage; T=total No of studies; T2DM=type 2 diabetes mellitus. *1 serving/week increment. †355 mL/d increment. ‡250 mL/d increment. §1 serving/d increment. ¶25 g/d increment. **Hazard ratio. †Children
Fig 2 Significant dose-response relations between dietary sugar consumption and multiple health outcomes. Estimates are relative risks, summary mean difference is weighted mean difference, and effect models are random unless noted otherwise. Δ=final value – baseline value; AMSTAR=a measurement tool to assess systematic reviews; C=cohort studies; CHD=coronary heart disease; CI=confidence interval; CVD=cardiovascular disease; GRADE=Grading of Recommendations Assessment, Development and Evaluation; NA=not available; P=population based case-control and/or cross sectional studies; SSB=sugar sweetened beverage; T=total No of studies; T2DM=type 2 diabetes mellitus. *1 serving/week increment. †355 mL/d increment. ‡250 mL/d increment. §1 serving/d increment. ¶25 g/d increment. **Hazard ratio. †ChildrenCC BY · PubMed Central
Fig 3 Significant non-dose-response relations between dietary sugar consumption and endocrine and metabolic outcomes. Comparisons are highest versus lowest, estimates are relative risks, summary mean difference is weighted mean difference, and effect models are random unless noted otherwise. Complete associations between dietary sugar consumption and endocrine and metabolic outcomes are shown in supplementary table A. Δ=final value – baseline value; AMSTAR=a measurement tool to assess systematic reviews; C=cohort studies; CI=confidence interval; GRADE=Grading of Recommendations Assessment, Development and Evaluation; HDL-C=high density lipoprotein cholesterol; LADA=latent autoimmune diabetes in adults; LDL-C=low density lipoprotein cholesterol; NA=not available; P=population based case-control and/or cross sectional studies; R=randomised controlled trials; SSB=sugar sweetened beverage; T=total No of studies. *Odds ratio. †Children. ‡Any versus none. §Fixed effects model. ¶Standardised mean difference
Fig 3 Significant non-dose-response relations between dietary sugar consumption and endocrine and metabolic outcomes. Comparisons are highest versus lowest, estimates are relative risks, summary mean difference is weighted mean difference, and effect models are random unless noted otherwise. Complete associations between dietary sugar consumption and endocrine and metabolic outcomes are shown in supplementary table A. Δ=final value – baseline value; AMSTAR=a measurement tool to assess systematic reviews; C=cohort studies; CI=confidence interval; GRADE=Grading of Recommendations Assessment, Development and Evaluation; HDL-C=high density lipoprotein cholesterol; LADA=latent autoimmune diabetes in adults; LDL-C=low density lipoprotein cholesterol; NA=not available; P=population based case-control and/or cross sectional studies; R=randomised controlled trials; SSB=sugar sweetened beverage; T=total No of studies. *Odds ratio. †Children. ‡Any versus none. §Fixed effects model. ¶Standardised mean differenceCC BY · PubMed Central
Fig 4 Significant non-dose-response relations between dietary sugar consumption and cardiovascular outcomes. Comparisons are highest versus lowest, estimates are relative risks, summary mean difference is weighted mean difference, and effect models are random unless noted otherwise. Complete associations between dietary sugar consumption and cardiovascular outcomes are shown in supplementary table B. Δ=final value – baseline value; AMSTAR=a measurement tool to assess systematic reviews; C=cohort studies; CI=confidence interval; CVD=cardiovascular disease; GRADE=Grading of Recommendations Assessment, Development and Evaluation; NA=not available; P=population based case-control and/or cross sectional studies; SBP=systolic blood pressure; SSB=sugar sweetened beverage; T=total No of studies. *Children and adolescents. †Odds ratio
Fig 4 Significant non-dose-response relations between dietary sugar consumption and cardiovascular outcomes. Comparisons are highest versus lowest, estimates are relative risks, summary mean difference is weighted mean difference, and effect models are random unless noted otherwise. Complete associations between dietary sugar consumption and cardiovascular outcomes are shown in supplementary table B. Δ=final value – baseline value; AMSTAR=a measurement tool to assess systematic reviews; C=cohort studies; CI=confidence interval; CVD=cardiovascular disease; GRADE=Grading of Recommendations Assessment, Development and Evaluation; NA=not available; P=population based case-control and/or cross sectional studies; SBP=systolic blood pressure; SSB=sugar sweetened beverage; T=total No of studies. *Children and adolescents. †Odds ratioCC BY · PubMed Central
Fig 5 Significant non-dose-response relations between dietary sugar consumption and cancer outcomes. Comparisons are highest versus lowest, estimates are relative risks, and effect models are random unless noted otherwise. Complete associations between dietary sugar consumption and cancer outcomes are shown in supplementary table C. AMSTAR=a measurement tool to assess systematic reviews; GRADE=Grading of Recommendations Assessment, Development and Evaluation; C=cohort studies; CI=confidence interval; NA=not available; P=population based case-control and/or cross sectional studies; SSB=sugar-sweetened beverage; T=total No of studies
Fig 5 Significant non-dose-response relations between dietary sugar consumption and cancer outcomes. Comparisons are highest versus lowest, estimates are relative risks, and effect models are random unless noted otherwise. Complete associations between dietary sugar consumption and cancer outcomes are shown in supplementary table C. AMSTAR=a measurement tool to assess systematic reviews; GRADE=Grading of Recommendations Assessment, Development and Evaluation; C=cohort studies; CI=confidence interval; NA=not available; P=population based case-control and/or cross sectional studies; SSB=sugar-sweetened beverage; T=total No of studiesCC BY · PubMed Central
Fig 6 Significant non-dose-response relations between dietary sugar consumption and other outcomes. Comparisons are highest versus lowest, estimates are relative risks, summary mean difference is weighted mean difference, and effect models are random unless noted otherwise. Complete associations between dietary sugar consumption and other outcomes are shown in supplementary table D. ADHD=attention deficit/hyperactivity disorder; AMSTAR=a measurement tool to assess systematic reviews; BMD=bone mineral density; C=cohort studies; CI=confidence interval; GRADE=Grading of Recommendations Assessment, Development and Evaluation; IHCL=intrahepatocellular lipids; NA=not available; NAFLD=non-alcoholic fatty liver disease; P=population based case-control and/or cross sectional studies; R=randomised controlled trials; SSB=sugar-sweetened beverage; T=total No of studies. *Children. †Odds ratio. ‡Fixed effects model. §Never/low versus moderate/high consumption. ¶Standardised mean difference. **Any versus none
Fig 6 Significant non-dose-response relations between dietary sugar consumption and other outcomes. Comparisons are highest versus lowest, estimates are relative risks, summary mean difference is weighted mean difference, and effect models are random unless noted otherwise. Complete associations between dietary sugar consumption and other outcomes are shown in supplementary table D. ADHD=attention deficit/hyperactivity disorder; AMSTAR=a measurement tool to assess systematic reviews; BMD=bone mineral density; C=cohort studies; CI=confidence interval; GRADE=Grading of Recommendations Assessment, Development and Evaluation; IHCL=intrahepatocellular lipids; NA=not available; NAFLD=non-alcoholic fatty liver disease; P=population based case-control and/or cross sectional studies; R=randomised controlled trials; SSB=sugar-sweetened beverage; T=total No of studies. *Children. †Odds ratio. ‡Fixed effects model. §Never/low versus moderate/high consumption. ¶Standardised mean difference. **Any versus noneCC BY · PubMed Central
Fig 7 Map of outcomes associated with dietary sugar consumption
Fig 7 Map of outcomes associated with dietary sugar consumptionCC BY · PubMed Central

Verification

Claims the paper makes

76 Valid · 2 Not valid · 68 Not checked · 65 Own results and interpretations

138 more claims · 64 with their cited sources checked

Create a free account to see all 211 claims and to verify the 102 references still open.

See all claims — free account
  • It may state two separate claims as one. 47
  • Probably not a substantial claim. 26

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 153 · Cited by 348

Metadata

Authors
Huang, Y., Chen, Z., Chen, B., Li, J., Yuan, X., Li, J., Wang, W., Dai, T., Chen, H., Wang, Y., Wang, R., Wang, P., Guo, J., Dong, Q., Liu, C., Wei, Q., Cao, D., & Liu, L.
Affiliations
  • Sichuan University (CN)
  • University of California Davis Medical Center (US)
Corresponding author
Liu, Liangren
Venue
BMJ
Publisher
BMJ
Published
2023-04-05
Volume
381
Pages
e071609
ISSN
1756-1833 (ISSN-L)
OpenAlex
W4362636766
Cited by
348
References
153
Citations by year
2026: 106 · 2025: 117 · 2024: 104 · 2023: 21
FWCI
70.78
Type
journal article
Language
en
Open access
Locations
  • BMJ (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China
  • Department of Science and Technology of Sichuan Province
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
  • Health Sciences › Nursing › Nutrition and Dietetics › Biochemical Analysis and Sensing Techniques
Keywords
sugar consumption, free sugars, added sugars, sugar-sweetened beverages, fructose, body weight, ectopic fat deposition, gout, coronary artery disease, all-cause mortality, pancreatic cancer, cardiometabolic disease, cancer risk, dental health, neuropsychiatric outcomes
MeSH terms
Dietary Sugars, Sugars, Systematic Reviews as Topic, Beverages, Cross-Sectional Studies, Humans, Meta-Analysis as Topic, Weight Gain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dietary sugar consumption and health: umbrella review. https://app.cochat.ai/papers/10.1136/bmj-2022-071609
The paper
Huang, Y., Chen, Z., Chen, B., Li, J., Yuan, X., Li, J., Wang, W., Dai, T., Chen, H., Wang, Y., Wang, R., Wang, P., Guo, J., Dong, Q., Liu, C., Wei, Q., Cao, D., & Liu, L. (2023). Dietary sugar consumption and health: umbrella review. BMJ. https://doi.org/10.1136/bmj-2022-071609

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.